A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension

Trial Profile

A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Interstitial cystitis; Pain
  • Focus Therapeutic Use
  • Sponsors Allergan; TARIS Biomedical
  • Most Recent Events

    • 19 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 24 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 09 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top